At-a-Glance
- Outlook Therapeutics enters exclusive Swiss distribution partnership with Mediconsult AG.
- Mediconsult to pursue Swiss Marketing Authorization and lead LYTENAVA™ (bevacizumab gamma) commercialization.
- LYTENAVA™ has centralized EU approval (European Commission) and UK MHRA approval for wet AMD.
- Swiss launch expected in 2027, pending regulatory approval.
Edited and Written By: Pharmacally Medical News Desk Assisted By: Karthikteja Macharla, PharmD
Reviewed By: Pharmacally Editorial Team
Outlook Therapeutics, Inc. a biopharmaceutical company advancing bevacizumab-based treatments for retinal diseases, has signed an exclusive commercial distribution agreement with Mediconsult AG, Switzerland’s premier full-service provider for ophthalmic professionals. This deal grants Mediconsult sole rights to market, import, distribute, and commercialize LYTENAVA™ (bevacizumab gamma) in Switzerland under Outlook Therapeutics’ trademark.
Under the agreement, Mediconsult takes charge of all Switzerland-specific regulatory tasks, including obtaining and sustaining Marketing Authorization (MA) from Swissmedic, Switzerland’s regulatory authority. The company will also drive commercialization efforts, leveraging its 35+ years of ophthalmology expertise and established relationships with key stakeholders like ophthalmologists and clinics.
Outlook Therapeutics retains control over manufacturing, product supply, and intellectual property, ensuring consistent quality and global oversight.
“This partnership aligns with our goal of broadening LYTENAVA™ access across Europe while upholding rigorous manufacturing standards,” said Bob Jahr, CEO of Outlook Therapeutics.
Mediconsult CEO Thomas Sammer, Ph.D., echoed this enthusiasm: “LYTENAVA™ offers a vital option for wet AMD patients, and our regulatory and commercial strengths will facilitate a smooth launch.”
LYTENAVA™ is an investigational ophthalmic formulation of bevacizumab in the U.S., but it has secured a centralized MA from the European Commission for wet age-related macular degeneration (wet AMD) across the EU, plus approval from the UK’s MHRA.
Availability in Switzerland is targeted for 2027, pending Swiss MA approval. In select EU states, pricing and reimbursement decisions remain additional hurdles.
Mechanism of Action and Clinical Relevance
LYTENAVA™ sterically block VEGF’s interaction with receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on endothelial cells, it inhibits endothelial proliferation, vascular leakage, and pathological neovascularization in the retina. Administered via intravitreal injection, it addresses core drivers of wet AMD, a leading cause of vision loss.
This move expands Outlook’s European footprint following EU and UK approvals, targeting high-value markets like Switzerland, which boasts advanced ophthalmology infrastructure.
Reference
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland, 19 February 2026, https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeutics-expands-european-footprint-exclusive